Archives

Categories

About

Subscribe to this blog's feed
Add me to your TypePad People list

Copyright notice

  • TNFMedicine.com © 2007 Edward Lewis Tobinick MD, A Medical Corporation. All Rights Reserved.

Disclaimer

  • The views expressed in this blog are my personal thoughts and opinions. I maintain this blog for my own use, to categorize important medical information for myself as it develops. Posts are for informational and educational purposes only. This blog does not constitute medical advice, and none of its posts should be interpreted or relied on as such. This blog does not constitute a solicitation for business. No claims, promises, or guarantees about the accuracy of the information herein are made. Sending me an e-mail does not create a physician-patient relationship. Many of the posts herein contain abstracts and citations which are publically available at www.pubmed.gov, the online medical article database from the National Library of Medicine(which has no affiliation with this site). Many of the posts contain information regarding off-label uses of biologic TNF antagonists. This website should not be interpreted to imply or explicitly make or propose any treatment recommendations. The off-label uses discussed on this website are uses which are, by definition, not FDA-approved. Therefore the safety and efficacy of these uses have not yet been confirmed nor endorsed by the FDA, and no recommendation regarding the use of these reported methods is inferred or implied by their inclusion on this website. Biologic TNF-anatagonists, such as etanercept, infliximab, and adalimumab can have serious adverse effects, such as death, infection, cytopenias, and may be associated with an increased risk of lymphoma, demyelinating disease, eye inflammation, and congestive heart failure. Medical consultation prior to their use is mandatory.

Patent Notice

  • The following U.S. patents have been issued to Edward Tobinick MD concerning selected uses of certain biologic TNF antagonists and other cytokine antagonists for selected neurological and related indications in humans: 6,015,557; 6,177,077; 6,379,666; 6,419,934; 6,419,944; 6,423,321; 6,471,961; 6,428,787; 6,537,549; 6,982,089. Also Australian patent 758,523. Additional U.S. and foreign patents are pending.

« Perispinal TNF-alpha inhibition for discogenic pain. | Main | Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. »

January 22, 2007

Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene.

Clin Rheumatol. 2006 Aug 29; [Epub ahead of print]
Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene.

Serratrice J,
de Roux-Serratrice C,
Disdier P,
Dode C,
Weiller PJ.
Service de Medecine Interne, du Professeur Pierre Jean Weiller, CHU de La Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 05, France, patrick.disdier@ap-hm.fr.
An adult patient experienced attacks of severe low back pain and sciatic neuralgia for several years, sometimes associated with myalgias, skin lesions, and high fever. Specific inflammatory laboratory tests were the major abnormalities. P46L mutation in the gene on chromosome 12p13 that encodes tumor necrosis factor receptor superfamily 1A (TNFRSF1A) was found. Management with anti-TNF agent was effective with a complete remission of bouts of pain and fever.
PMID: 16941196 [PubMed - as supplied by publisher]

Posted at 08:49 PM in TNF and Back Pain/Sciatica, TNF and off-label use |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83421064353ef00d83572367d69e2

Listed below are links to weblogs that reference Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene.:

Comments

The comments to this entry are closed.